-
Mashup Score: 2
Median overall survival reached 20 years with interferon alfa-2b in low-grade disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Pre-Existing Heart Failure Tied to Higher Mortality in Lymphoma - 1 year(s) ago
DLBCL patients with HF 45% less likely to receive standard first-line anthracyclines, study found
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Patients with #DLBCL and pre-existing heart failure were less likely to receive standard, but #cardiotoxic, #anthracycline treatment, likely resulting in worse survival outcomes. @JenicaUpshaw @Tufts_ICRHPS #HF #MedTwitter #OncoTwitter https://t.co/PWR075dMbn
-
-
Mashup Score: 0
Prospective study in heavily treated population is warranted, researcher says
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Almost 80% of #VTEs occurred in patients who had received three or more #chemotherapy regimens, a retrospective study by @ErikaJLampert showed. #OncoTwitter #MedTwitter @SGO_org #SGOMTG #SGO2023 https://t.co/OIXYIkSKkt
-
-
Mashup Score: 0
News, features, and commentary about cancer-related issues
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Hey #OncTwitter! Here's what you may have missed this week: https://t.co/TUhAc5HtFV (Thread)
-
-
Mashup Score: 0Few Sickle Cell Disease Patients Are Adequately Treated for Pain - 1 year(s) ago
Under 4% of patients have prescriptions for appropriate drugs
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
"Less than 5% of the people who would benefit from these medications are getting them," said Robert Cronin, MD, of Ohio State University, on the lack of useful medications provided to patients with #sicklecelldisease. #MedTwitter https://t.co/fWBFX6iU1o
-
-
Mashup Score: 0Discordant Biomarkers Foretell Prognosis in Oropharyngeal Cancer - 1 year(s) ago
Patients who were p16 and HPV discordant had worse survival than those who were double positive
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Mismatch between the p16 protein and #HPV biomarkers can help determine prognosis in patients with #oropharyngealcancer, according to @h_mehanna. https://t.co/KIUESeqJfB
-
-
Mashup Score: 0
Consider ‘trade-offs’ between harms and benefits of treatments, say researchers
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
For #prostatecancers detected by screening, cancer-specific mortality was low at 15-year follow-up regardless of whether patients underwent active monitoring, prostatectomy, or radiotherapy, reported Freddie C. Hamdy, MD. https://t.co/LL7lgr3xdF #MedTwitter
-
-
Mashup Score: 0Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers - 1 year(s) ago
ZIRCON trial meets sensitivity and specificity targets
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
An investigational PET imaging agent -- zirconium-89 (89Zr)-deferoxamine (DFO)-girentuximab -- identified clear cell renal cell carcinoma with high sensitivity and specificity, reported Peter Mulders, MD, PhD. https://t.co/7SNYURT5Tu
-
-
Mashup Score: 0FDA Panel Endorses New First-Line Lymphoma Regimen - 1 year(s) ago
POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Despite the concerns of FDA staff, agency advisors endorsed the inclusion of polatuzumab vedotin (Polivy) in a modified version of R-CHOP for adults w/ previously untreated large B-cell #lymphoma.@Dr_RaviMadan @Maryam_Yazdy @ChrisRFlowersMD @MikkaelSekeres https://t.co/az1tIZgUnm
-
-
Mashup Score: 0
Choice of agent, post-progression treatment, and resistance mechanisms top unanswered questions
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
Emerging data have helped optimize the use of CDK4/6 inhibitors in metastatic HR-positive #breastcancer, and the focus has turned to overcoming resistance, said Priyanka Sharma, MD, of @KUHospital, during #MBCC23. https://t.co/gvxyb7DkPm
-
"I think the results of this study represent a significant contribution to determining the standard-of-care #treatment for this rare #disease,"--@MelanicjMD of @NCIResearchCtr. #OncoTwitter #MedTwitter https://t.co/gqCOaFihe8